Week In Review: JHL Biotech Signs $257 Million Biosimilar Deal With Sanofi
December 10, 2016 at 12:44 PM EST
JHL Biotech, a Taiwan-China biologics company, signed a $257 million partnership agreement that gives Sanofi rights to market a JHL clinical-stage rituximab biosimilar, initially for China.
